Longitudinal profiling of soluble immune checkpoint proteins in oropharyngeal squamous cell carcinoma: treatment-associated dynamics and exploratory associations with disease stage and relapse-free survival

Introduction Oropharyngeal squamous cell carcinoma (OPSCC) is now predominantly associated with human papillomavirus (HPV), particularly HPV16, and is characterized by a distinct immune landscape and a generally favorable prognosis. Nonetheless, a subset of patients relapses following curative treatment, emphasizing the need for biomarkers that capture dynamic systemic immune regulation beyond tissue-based analyses. Soluble immune checkpoint proteins (sICPs) are biologically active circulating mediators that may reflect the balance between anti-tumor immunity and immune tolerance. Methods In this prospective observational study, we longitudinally profiled serum levels of 17 sICPs in 77 patients with OPSCC who received curative-intent radiotherapy, with or without chemotherapy. Serum samples were collected at three time points: pre-treatment (baseline), 7 weeks after treatment initiation, and at 12 months after treatment completion, and analyzed in relation to sampling time point, tumor stage, treatment modality, and clinical outcome. Results Among 65 HPV16 + /p16 + patients, distinct treatment-associated temporal changes were observed, including a transient increase in soluble TIM-3 and a concomitant decrease in soluble PD-1 during active therapy, followed by partial recovery at long-term follow-up. At 12 months after treatment completion, soluble CD40 levels were elevated, while soluble TLR-2 levels were reduced, indicating persistent remodeling of systemic immune regulation beyond active treatment. Tumor stages II-IVA were associated with increased baseline levels of inhibitory sICPs, including soluble GITRL and soluble CTLA-4, compared with stage I, and a trend toward reduced soluble CD80 levels, suggesting a more immunosuppressive systemic milieu in advanced disease. Importantly, elevated pre-treatment soluble PD-1 was associated with poorer relapse-free survival in the entire cohort of 77 patients, although this association was not observed in the HPV16 + /p16 + subgroup alone. No other sICP retained prognostic significance after correction for multiple testing. Discussion Given the sample size and limited number of events, the association between baseline sPD-1 and RFS in the entire cohort should be regarded as hypothesis-generating. Together, these findings indicate that circulating sICPs undergo dynamic and sustained changes during and after treatment and support further investigation of their associations with systemic immune status and clinical outcomes in larger, prospectively powered OPSCC cohorts.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.2000339
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Longitudinal profiling of soluble immune checkpoint proteins in oropharyngeal squamous cell carcinoma: treatment-associated dynamics and exploratory associations with disease stage and relapse-free survival

Lindstedt M., Tiblom Ehrsson Y., Laurell G., Greiff L. et al.
1 links
Frontiers in Oncology
Head and Neck Cancer Studies
article

Longitudinal profiling of soluble immune checkpoint proteins in oropharyngeal squamous cell carcinoma: treatment-associated dynamics and exploratory associations with disease stage and relapse-free survival

Lindstedt M., Tiblom Ehrsson Y., Laurell G., Greiff L., Sakellariou C., Ajazi K.
article en

Abstract

Introduction Oropharyngeal squamous cell carcinoma (OPSCC) is now predominantly associated with human papillomavirus (HPV), particularly HPV16, and is characterized by a distinct immune landscape and a generally favorable prognosis. Nonetheless, a subset of patients relapses following curative treatment, emphasizing the need for biomarkers that capture dynamic systemic immune regulation beyond tissue-based analyses. Soluble immune checkpoint proteins (sICPs) are biologically active circulating mediators that may reflect the balance between anti-tumor immunity and immune tolerance. Methods In this prospective observational study, we longitudinally profiled serum levels of 17 sICPs in 77 patients with OPSCC who received curative-intent radiotherapy, with or without chemotherapy. Serum samples were collected at three time points: pre-treatment (baseline), 7 weeks after treatment initiation, and at 12 months after treatment completion, and analyzed in relation to sampling time point, tumor stage, treatment modality, and clinical outcome. Results Among 65 HPV16 + /p16 + patients, distinct treatment-associated temporal changes were observed, including a transient increase in soluble TIM-3 and a concomitant decrease in soluble PD-1 during active therapy, followed by partial recovery at long-term follow-up. At 12 months after treatment completion, soluble CD40 levels were elevated, while soluble TLR-2 levels were reduced, indicating persistent remodeling of systemic immune regulation beyond active treatment. Tumor stages II-IVA were associated with increased baseline levels of inhibitory sICPs, including soluble GITRL and soluble CTLA-4, compared with stage I, and a trend toward reduced soluble CD80 levels, suggesting a more immunosuppressive systemic milieu in advanced disease. Importantly, elevated pre-treatment soluble PD-1 was associated with poorer relapse-free survival in the entire cohort of 77 patients, although this association was not observed in the HPV16 + /p16 + subgroup alone. No other sICP retained prognostic significance after correction for multiple testing. Discussion Given the sample size and limited number of events, the association between baseline sPD-1 and RFS in the entire cohort should be regarded as hypothesis-generating. Together, these findings indicate that circulating sICPs undergo dynamic and sustained changes during and after treatment and support further investigation of their associations with systemic immune status and clinical outcomes in larger, prospectively powered OPSCC cohorts.

Frontiers in OncologyVol. 16
Uppsala University (SE), Lund University (SE), Skåne University Hospital (SE)
Cancerfonden, Fru Berta Kamprads Stiftelse, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Good health and well-being
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon